US 12,268,718 B2
Control of cellular redox levels
Elizabeth McKenna, Houston, TX (US)
Filed by Labyrinth Holdings LLC, Sugar Land, TX (US)
Filed on Nov. 10, 2016, as Appl. No. 15/348,005.
Application 15/348,005 is a continuation in part of application No. 14/640,075, filed on Mar. 6, 2015, granted, now 9,931,398.
Application 14/640,075 is a continuation of application No. 14/034,044, filed on Sep. 23, 2013, abandoned.
Application 14/640,075 is a continuation of application No. 13/743,194, filed on Jan. 16, 2013, granted, now 9,713,630.
Claims priority of provisional application 62/253,542, filed on Nov. 10, 2015.
Claims priority of provisional application 61/704,090, filed on Sep. 21, 2012.
Claims priority of provisional application 61/586,975, filed on Jan. 16, 2012.
Prior Publication US 2017/0232047 A1, Aug. 17, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/747 (2015.01); A61K 35/742 (2015.01); A61K 35/744 (2015.01); A61K 38/48 (2006.01); A61K 45/00 (2006.01); C12N 1/06 (2006.01); C12N 1/20 (2006.01); G01N 33/88 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/68 (2006.01)
CPC A61K 35/747 (2013.01) [A61K 35/742 (2013.01); A61K 35/744 (2013.01); A61K 38/482 (2013.01); A61K 45/00 (2013.01); C12N 1/06 (2013.01); C12N 1/20 (2013.01); C12Y 304/21043 (2013.01); G01N 33/88 (2013.01); A61K 9/0056 (2013.01); A61K 9/0058 (2013.01); A61K 9/2004 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7009 (2013.01)] 10 Claims
 
1. A method of regulating redox status in a subject, the method comprising administering a therapeutically effective amount of a composition to a subject in need thereof, the composition comprising:
(a) at least one lysate of an inactivated Gram-positive bacterium comprising the entire cellular contents of the bacterium cell, wherein the lysate of the Gram-positive bacterium comprises a toll-like receptor (TLR) agonist that regulates redox status in the subject, wherein the TLR agonist activates two or more TLRs, wherein the two or more TLRs comprise TLR2 and TLR4, and wherein the Gram-positive bacterium is inactivated by a heat treatment of the Gram-positive bacterium and by a lysozyme treatment of the Gram-positive bacterium;
(b) an optional promoter for enhancing absorption of the composition; and
(c) an optional carrier for increasing a volume of the composition,
wherein redox status regulation is assessed by measuring changes in isoprostane concentration in a subject and wherein administration of an effective amount of the composition to the subject measurably reduces oxidative stress levels and decreases isoprostane concentration in the subject.